Please login to the form below

Not currently logged in
Email:
Password:

STEM

This page shows the latest STEM news and features for those working in and with pharma, biotech and healthcare.

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

CTX001 is an investigational, autologous, gene-edited haematopoietic stem cell therapy for patients suffering from severe haemoglobinopathies. ... CTX001 is an investigational ex vivo CRISPR gene-edited therapy for patients suffering from β-thalassemia

Latest news

  • CHMP delays decision on Kiadis’ GVHD immunotherapy CHMP delays decision on Kiadis’ GVHD immunotherapy

    ATIR101 is a novel cell therapy which aims to help improve outcomes in patients who receive  hematopoietic stem cell translation (HSCT) for certain types of blood cancer. ... During the HSCT treatment, the patient’s bone marrow is completely destroyed

  • EMA to review Bluebird’s blood disorder gene therapy EMA to review Bluebird’s blood disorder gene therapy

    Another option for TDT patients is bone marrow transplant (allogeneic haematopoietic stem cell transplant or allo-HSCT), which has the potential to correct the genetic deficiency. ... The therapy itself works by inserting a functional human beta-globin

  • Medtech's mixed-up monsters Medtech's mixed-up monsters

    The reasons for this persistent and well-recognised hatred are complicated. Mostly, they stem from the belief that any synergies between the diverse businesses are worth less than the negative implications

  • London cancer hub launched by Cancer Research UK London cancer hub launched by Cancer Research UK

    She underwent a stem cell transplant but unfortunately her leukaemia did not respond. ... These CAR-T cells were generated using a donation from her brother who was also her original stem cell donor.

  • NICE turns down Opdivo for adjuvant melanoma therapy NICE turns down Opdivo for adjuvant melanoma therapy

    The draft guidance – which is out for public comment until 28 September – says that the uncertainty about Opdivo’s benefits stems from having “no trials directly comparing adjuvant nivolumab with routine

More from news
Approximately 16 fully matching, plus 358 partially matching documents found.

Latest Intelligence

  • Brand teams: why are some smarter than others? Brand teams: why are some smarter than others?

    They stem from different philosophies of knowledge. They take as their inputs different kinds of information from different sources.

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Raju Prasad says Bluebird can offer a compelling cost-effectiveness case for its treatment in beta thalassemia and sickle cell cases versus conventional stem cell treatment. ... Conventional stem cell transplants cost anywhere between $500, 000 and $1m,

  • 30 women leaders in UK healthcare (part 3) 30 women leaders in UK healthcare (part 3)

    Kathy Niakan is a group leader investigating the mechanisms of lineage specification in human embryos and stem cells, and was the first person ever to be granted a licence to conduct

  • Reaching the new influencers Reaching the new influencers

    Right now, we’re living through healthcare’s age of accelerations - as evidenced by advances in everything from biotechnology and stem cell research to machine learning and the advent (and approvals)

  • Changes to look out for in Medical Devices Regulations Changes to look out for in Medical Devices Regulations

    Issues from PIP silicone breast implants and metal-on-metal hips stem from very different root causes - the first from deliberate subversion of the regulatory system and the second from unanticipated

More from intelligence
Approximately 1 fully matching, plus 48 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader.

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory

  • Simon Doyle joins STEM Simon Doyle joins STEM

    Simon Doyle joins STEM. He takes up a position as vice president, global customer relations development. ... Benchmarking company STEM has appointed Simon Doyle as its new vice president of global customer relations and development.

  • Storm Therapeutics bolsters its team Storm Therapeutics bolsters its team

    As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells.

  • Porterhouse Medical promotes Emma Conran Porterhouse Medical promotes Emma Conran

    Conran has served in medical writing positions at Porterhouse Medical since 2014 and prior to that she was a translational stem cell biology lecturer at King’s College London.

More from appointments
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • The gene therapy revolution

    As an example, in the case of Strimvelis (autologous CD34. cells transduced to express adenosine deaminase [ADA]), the first ex vivo stem cell gene therapy approved by the EMA (European Medicines ... 1. The ground-breaking treatment uses a virus to

  • More tell, less sell: HCP-centric comms

    The role of doctors was recently eloquently described[6] as ‘ walking a tightrope’, where the source of difficulty stems not from doctors’ inherent commitment or ability to balance, but from the ... I would go as far as to say that any

  • Successful brands tell stories

    The brand story stems from the positioning, which articulates the essence of the narrative.

  • Training the next generation of biotech leaders

    Brexit and the skills shortage. Dr Ivan Wall is an expert in all things stem cell.

  • Biotech: it's a people business

    From Johnson &Johnson’ s immunology treatments to Pfizer’ s work on a stem cell-based remedy for age-related macular degeneration, pharma companies are quickly realising biotechnology is the future of

More from PMHub
Approximately 3 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics